Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on TG Therapeutics (TGTX – Research Report) and Mineralys Therapeutics, Inc. (MLYS – Research Report).
TG Therapeutics (TGTX)
Bank of America Securities analyst Alec Stranahan maintained a Sell rating on TG Therapeutics on September 8 and set a price target of $6.00. The company’s shares closed last Friday at $10.39.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for TG Therapeutics with a $26.14 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Mineralys Therapeutics, Inc. (MLYS)
Bank of America Securities analyst Greg Harrison maintained a Buy rating on Mineralys Therapeutics, Inc. yesterday and set a price target of $39.00. The company’s shares closed last Friday at $11.85, close to its 52-week low of $11.30.
According to TipRanks.com, Harrison is a 3-star analyst with an average return of
Mineralys Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $38.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TGTX:
- New Sales Data Hits TG Therapeutics (NASDAQ:TGTX) Hard
- TG Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- A Big Insider Buy Prompts Gains at TG Therapeutics (NASDAQ:TGTX)
- TG Therapeutics call volume above normal and directionally bullish
- TG Therapeutics upgraded to Neutral from Sell at Goldman Sachs
